Monte Rosa Therapeutics (GLUE) Retained Earnings (2020 - 2026)

Monte Rosa Therapeutics' Retained Earnings history runs 7 years deep, the most recent figure standing at -$521.7 million for Q1 2026.

• In Q1 2026, Retained Earnings fell 33.19% year-over-year to -$521.7 million; the TTM figure through Mar 2026 stood at -$521.7 million (down 33.19% YoY), while the FY2025 annual figure was -$3.8 million, down 14.03% from the prior year.
• Retained Earnings for Q1 2026 stood at -$521.7 million, down from -$3.8 million in the prior quarter.
• The five-year high for Retained Earnings was -$1.5 million in Q3 2023, with the low at -$521.7 million in Q1 2026.
• The 5-year median for Retained Earnings is -$3.4 million (2025), against an average of -$138.8 million.
• The sharpest annual moves came in 2023 and 2025: Retained Earnings jumped 99.27% in 2023, then plunged 14445.12% in 2025.
• Monte Rosa Therapeutics' Retained Earnings stood at -$230.5 million in 2022, then jumped by 98.82% to -$2.7 million in 2023, then retreated by 23.2% to -$3.4 million in 2024, then decreased by 14.03% to -$3.8 million in 2025, then sank by 13532.53% to -$521.7 million in 2026.
• Business Quant data shows GLUE's Retained Earnings at -$521.7 million in Q1 2026, -$3.8 million in Q4 2025, and -$3.2 million in Q3 2025.